Search bioRxiv⌕ Search

Biology subjects

Kranthi, D.

Publications and source records attributed to Kranthi, D..

2 recordsLinked to original sources

A Hybrid Physics-Deep Learning Framework for Combinatorial De Novo Design of Small-Molecule Binding Proteins

Engineering small-molecule binding proteins de novo remains a significant challenge as even advanced generative models struggle to model the atom-level details of protein-ligand interactions with sufficient accuracy. Higher experimental success rates have resulted from methods that explicitly scaffold predefined binding interactions into helical bundles. Here we introduce a scaffolding strategy that generalizes to alpha-beta architectures. By screening thousands of combinatorially assembled protein-ligand interactions against diverse de novo backbones with finely varied pocket geometries, the protocol allows for high-fidelity accommodation of target interaction geometries. Our protocol then integrates physics-based and deep learning methods for optimization of interfacial interactions and sequence-structure compatibility, considerably improving in silico design metrics. Applying this method to two chemically similar steroids achieved a notable experimental success rate (4/26 designs bind their targets), and NMR structures of two designs are in good agreement with design models. Our generalizable, atomically precise approach offers a robust framework for small-molecule binder design, effectively eliminating the need for high-throughput screening.

bioengineering↗

Structure based discovery of antipsychotic-like TAAR1 agonists

Schizophrenia is a severe mental illness whose current treatments primarily target dopamine and serotonin receptors. These drugs often cause side effects and vary in effectiveness across patients. The trace amine-associated receptor 1 (TAAR1), which modulates monoamine signaling, has emerged as a promising alternative target. To discover new TAAR1 ligands, we computationally docked 65 million molecules against the active state of TAAR1 and experimentally tested 55 of those highly ranked. Fourteen molecules active against TAAR1 with potencies ranging from mid-nanomolar to micromolar, all as agonists. This high functional selectivity may reflect the compact conformation adopted by the activated TAAR1 orthosteric site. While this was favorable for agonist prioritization, simulations suggest that it can be over-optimized for initial hit rates at the expense of subsequent affinity maturation. Here, hit optimization yielded nanomolar agonists whose docking-predicted poses were confirmed by cryo-EM. Three agonists had high brain exposure and potencies apparently better than the investigational drug ulotaront and sufficient for behavioral studies. All three potently normalized amphetamine-induced pre-pulse inhibition in mice, a model for schizophrenia, without catalepsy, a common side effect of traditional antipsychotics.

biochemistry↗